Task: Please answer the following question about the molecule with SMILES COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(=O)O.
Request: Please describe this drug.
Answer: Pegaptanib is a 28-mer RNA aptamer covalently linked to two branched 20-kD polyethylene glycol (PEG) chains, with anti-angiogenic activity. Pegaptanib binds and blocks the activity of the extracellular vascular endothelial growth factor, specifically the 165-amino acid isoform (VEGF165). This prevents VEGF165 from binding to VEGF receptors, thereby blocking angiogenesis as well as preventing VEGF165-induced increases in vessel permeability. VEGF165 is preferentially involved in pathological ocular neovascularisation.
Task: Please answer the following question about the molecule with {SMILES__description} {SMILES#}.
{#Description|Question|Request!}: {quest#}
{#Result|Answer|Completion!}: {answ#}
COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(=O)O
COCCOC(=O)NCCCC[C@@H](C(=O)NCCCCCCCOP(=O)(C)O)NC(=O)OCCOC
7-[[(2S)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinicacid
Please describe this drug.
Pegaptanib is a 28-mer RNA aptamer covalently linked to two branched 20-kD polyethylene glycol (PEG) chains, with anti-angiogenic activity. Pegaptanib binds and blocks the activity of the extracellular vascular endothelial growth factor, specifically the 165-amino acid isoform (VEGF165). This prevents VEGF165 from binding to VEGF receptors, thereby blocking angiogenesis as well as preventing VEGF165-induced increases in vessel permeability. VEGF165 is preferentially involved in pathological ocular neovascularisation.